This page has moved. Click here to view.
The prostate normally grows larger as men age. After age 40, benign prostatic hyperplasia commonly develops. BPH affects half of men by age 60, and at least 80% by age 80. Forty percent of 80 year old men will have had a prostatectomy benign prostatic hyperplasia, BPH, prostate enlargement, enlarged prostate.
Benign prostatic hyperplasia is a nonmalignant neoplasm of the prostate. It is not a precursor or predisposing factor to prostate cancer. BPH is the most common cause of obstructive or irritative voiding symptoms in
Treatment of Benign Prostatic Hyperplasia
Prostatic stromal tissue is controlled by the adrenergic nervous system. Alpha-1 receptors benign prostatic hyperplasia, BPH, prostate enlargement, enlarged prostate control 80% of the activity of prostatic smooth muscle cells, causing contraction of the benign prostatic hyperplasia, BPH, prostate enlargement, enlarged prostate, prostate specific antigen stromal component of the prostate.
Many men with palpably enlarged prostates are not symptomatic while some patients with small benign prostatic hyperplasia, BPH, prostate enlargement, enlarged prostate prostates have significant voiding symptoms or urinary retention.
Obstruction forces the bladder to generate higher pressures than normal to achieve micturition. Increased muscle mass in the bladder leads to reduced bladder elasticity and compliance, which manifest as a reduction in bladder capacity.
If the obstruction is not relieved, bladder smooth muscle begins to be replaced by connective tissue, leading to bladder failure. This process produces the classic obstructive voiding symptoms of hesitancy, intermittency, decreased force of the stream, postvoid dribbling, and a feeling of incomplete bladder emptying.
Clinical Benign Prostatic Hyperplasia, BPH, prostate enlargement, enlarged prostate Evaluation of Benign Prostatic Hypertrophy